Matsumoto, Tetsuya
Yuasa, Akira http://orcid.org/0000-0002-3699-7231
Miller, Ryan
Pritchard, Clive
Ohashi, Takahisa
Taie, Amer
Gordon, Jason
Article History
Accepted: 22 August 2022
First Online: 15 September 2022
Declarations
:
: This work was supported by Pfizer Japan Inc., who provided support for the model development/analysis and medical writing for this study.
: The authors declare the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: TM has been on the speakers’ bureau for Pfizer Japan Inc. and MSD K.K. AY and TO are full-time employees of Pfizer Japan Inc. RM, CP, and JG are employees of Health Economics and Outcomes Research Ltd., which received funding from Pfizer Japan Inc. to undertake the research outlined in this study. AT is a full-time employee of Pfizer R&D UK Limited. AY and AT hold stocks and stock options from Pfizer Inc.
: Not applicable.
: Not applicable.
: Not applicable.
: The anonymized patient data underlying this manuscript are derived from the Medical Data Vision database and the national surveillance program (Japan Nosocomial Infections Surveillance) and cannot be made available by the authors. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. The economic model was submitted with the manuscript for peer review.
: Except for confidential data associated with modeling and data analysis, all data are available from the corresponding author upon reasonable request.
: TM ensured applicability of the model and analysis to the Japanese clinical setting and provided expert guidance to that end. AY and JG conceptualized and designed the study. CP and RM were responsible for data analysis. AY and TO provided local data to inform the model. All authors contributed to interpretation of the results, preparation and review of the manuscript, and approval of the final manuscript for publication